Preventing eczema flares with topical corticosteroids or tacrolimus: Which is best?

British Journal of Dermatology

Volumn 164, Issue 2, 2011, Pages 231-233

  Williams, H C ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT; FLUTICASONE; METHYLPREDNISOLONE ACEPONATE; TACROLIMUS;

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; ECZEMA; HUMAN; KIDNEY CANCER; LIVER CANCER; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SKIN CANCER; SKIN DISEASE; SKIN THINNING; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ECZEMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 79551469295     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10205.x     Document Type: Review

References (15)

1. Hoare C, Li Wan Po A, Williams H,. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1-191.
2. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-6. (Pubitemid 38608590)
3. Williams HC, Wüthrich B,. The natural history of atopic dermatitis. In: Atopic Dermatitis (, Williams HC, ed.), Cambridge: Cambridge University Press, 2000; 41-59.
4. Healy E, Bentley A, Fidler C, Chambers C,. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol 2011; 164: 387-95.
5. Schmitt J, Von Kobyletzki L, Svensson A, Apfelbacher C,. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164: 415-28.
6. Williams HC,. Atopic dermatitis. N Engl J Med 2005; 352: 2314-24.
7. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326: 1367.
8. Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008; 58: 990-9.
9. Lu G, Ades AE,. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-24.
10. Chen SL, Yan J, Wang FS,. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat 2010; 21: 144-56.
11. Joint Formulary Committee. British National Formulary, 60th edn. London: British Medical Association and Royal Pharmaceutical Society, September 2010.
12. Williams HC,. New treatments for atopic dermatitis. Good news but how to use them is a muddle. BMJ 2002; 324: 1533-4.
13. Meurer M, Eichenfield LF, Ho V, et al. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. J Dermatolog Treat 2010; 21: 157-66.
14. Szczepanowska J, Reich A, Szepietowski JC,. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol 2008; 19: 614-18.
15. Hjalte F, Asseburg C, Tennvall GR,. Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden-with model applications for Denmark, Norway and Finland. J Eur Acad Dermatol Venereol 2010; 24: 474-80.